Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.020
-0.050 (-4.67%)
Mar 6, 2026, 9:54 AM EST - Market open

Citius Oncology Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22
Selling, General & Admin
18.7917.115.657.882.86
Research & Development
6.176.424.934.246.86
Operating Expenses
25.5323.5220.5712.129.71
Operating Income
-22.38-23.52-20.57-12.12-9.71
Interest Expense
-0.26-0.22---
Interest & Investment Income
0.060.04---
Pretax Income
-22.58-23.7-20.57-12.12-9.71
Income Tax Expense
1.061.060.580.581.15
Net Income
-23.64-24.76-21.15-12.7-10.87
Net Income to Common
-23.64-24.76-21.15-12.7-10.87
Shares Outstanding (Basic)
7773686834
Shares Outstanding (Diluted)
7773686834
Shares Change (YoY)
11.84%7.66%0.82%100.00%-
EPS (Basic)
-0.31-0.34-0.31-0.19-0.32
EPS (Diluted)
-0.31-0.34-0.31-0.19-0.32
EBIT
-22.38-23.52-20.57-12.12-9.71
Source: S&P Capital IQ. Standard template. Financial Sources.